Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256968 | 0.85 | ALDH1A1 (0.55) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL8320324 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDMEN1KMT2AKDM4E | |
| SCHEMBL7263838 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL7263836 | 0.80 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL12034449 | 0.78 | CDC7 (0.69) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL2498385 | 0.78 | NPC1 (0.72) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL288785 | 0.76 | ALDH1A1 (0.59) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL27899564 | 0.76 | ALDH1A1 (0.59) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL25297051 | 0.75 | TSHR (0.45) | ALDH1A1HPGDMEN1KMT2AHSD17B10 | |
| SCHEMBL29030777 | 0.75 | ALDH1A1 (0.40) | ALDH1A1HPGDMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2021-04-01 | — | — | US | disclosed |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-23 | — | — | US | disclosed |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3194030-B1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | NEW YORK BLOOD CENTER, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, | 2019-03-07 | — | — | US | disclosed |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-28 | — | — | US | disclosed |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-28 | — | — | US | disclosed |
| WO-2017035127-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2016044808-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | NEW YORK BLOOD CENTER, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10576059-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-20210093608-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-10413527-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-10869856-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-20190070146-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-20200163935-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-20170273943-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-20200231571-A1 | SUBSTITUTED PHENYLPYRROLECARBOXAMIDES WITH THERAPEUTIC ACTIVITY IN HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-11571409-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
| US-11059808-B2 | Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV | PAH, NPEPPS, DNPEP | ALDH1A1 1554/4885HPGD 2622/4885MEN1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.